Skip to main content
Top
Published in: Journal of Hematology & Oncology 1/2021

Open Access 01-12-2021 | Letter to the Editor

Therapeutic implications of cancer gene amplifications without mRNA overexpression: silence may not be golden

Authors: Amélie Boichard, Scott M. Lippman, Razelle Kurzrock

Published in: Journal of Hematology & Oncology | Issue 1/2021

Login to get access

Abstract

Amplifications of oncogenic genes are often considered actionable. However, not all patients respond. Questions have therefore arisen regarding the degree to which amplifications, especially non-focal ones, mediate overexpression. We found that a subset of high-level gene amplifications (≥ 6 copies) (from The Cancer Genome Atlas database) was not over-expressed at the RNA level. Unexpectedly, focal amplifications were more frequently silenced than non-focal amplifications. Most non-focal amplifications were not silenced; therefore, non-focal amplifications, if over-expressed, may be therapeutically tractable. Furthermore, specific silencing of high-level focal or non-focal gene amplifications may explain resistance to drugs that target the relevant gene product.
Appendix
Available only for authorised users
Literature
1.
go back to reference Gerlinger M, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366:883–92.CrossRef Gerlinger M, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366:883–92.CrossRef
2.
go back to reference Sicklick JK, et al. Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. Nat Med. 2019;25:744–50.CrossRef Sicklick JK, et al. Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. Nat Med. 2019;25:744–50.CrossRef
3.
go back to reference Adashek JJ, et al. Transcriptomic silencing as a potential mechanism of treatment resistance. JCI Insight. 2020;5:e134824.CrossRef Adashek JJ, et al. Transcriptomic silencing as a potential mechanism of treatment resistance. JCI Insight. 2020;5:e134824.CrossRef
4.
go back to reference Tycko B. Epigenetic gene silencing in cancer. J Clin Invest. 2000;105:401–7.CrossRef Tycko B. Epigenetic gene silencing in cancer. J Clin Invest. 2000;105:401–7.CrossRef
5.
go back to reference Huntzinger E, Izaurralde E. Gene silencing by microRNAs: contributions of translational repression and mRNA decay. Nat Rev Genet. 2011;12:99–110.CrossRef Huntzinger E, Izaurralde E. Gene silencing by microRNAs: contributions of translational repression and mRNA decay. Nat Rev Genet. 2011;12:99–110.CrossRef
6.
go back to reference Oliveira C, Faoro H, Alves LR, Goldenberg S. RNA-binding proteins and their role in the regulation of gene expression in Trypanosoma cruzi and Saccharomyces cerevisiae. Genet Mol Biol. 2017;40:22–30.CrossRef Oliveira C, Faoro H, Alves LR, Goldenberg S. RNA-binding proteins and their role in the regulation of gene expression in Trypanosoma cruzi and Saccharomyces cerevisiae. Genet Mol Biol. 2017;40:22–30.CrossRef
7.
go back to reference Vogt N, et al. Relationships linking amplification level to gene over-expression in gliomas. PLoS ONE. 2010;5(12):e14249.CrossRef Vogt N, et al. Relationships linking amplification level to gene over-expression in gliomas. PLoS ONE. 2010;5(12):e14249.CrossRef
8.
go back to reference Rodon J, et al. Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. Nat Med. 2019;25:751–8.CrossRef Rodon J, et al. Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. Nat Med. 2019;25:751–8.CrossRef
9.
go back to reference Uhlen M, et al. A pathology atlas of the human cancer transcriptome. Science. 2017;357(eaan2507):1–11. Uhlen M, et al. A pathology atlas of the human cancer transcriptome. Science. 2017;357(eaan2507):1–11.
10.
go back to reference Mermel CH, et al. GISTIC20 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011;12(4):R41.CrossRef Mermel CH, et al. GISTIC20 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011;12(4):R41.CrossRef
11.
go back to reference Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinform. 2011;12:323.CrossRef Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinform. 2011;12:323.CrossRef
12.
go back to reference Vivian J, et al. Toil enables reproducible, open source, big biomedical data analyses. Nat Biotechnol. 2017;35(4):314–6.CrossRef Vivian J, et al. Toil enables reproducible, open source, big biomedical data analyses. Nat Biotechnol. 2017;35(4):314–6.CrossRef
13.
go back to reference Eijkelenboom A, et al. Recommendations for the clinical interpretation and reporting of copy number gains using gene panel NGS analysis in routine diagnostics. Virchows Arch. 2019;474:673–80.CrossRef Eijkelenboom A, et al. Recommendations for the clinical interpretation and reporting of copy number gains using gene panel NGS analysis in routine diagnostics. Virchows Arch. 2019;474:673–80.CrossRef
Metadata
Title
Therapeutic implications of cancer gene amplifications without mRNA overexpression: silence may not be golden
Authors
Amélie Boichard
Scott M. Lippman
Razelle Kurzrock
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2021
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/s13045-021-01211-1

Other articles of this Issue 1/2021

Journal of Hematology & Oncology 1/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine